Baker McKenzie has advised CH2 Holdings Pty Limited (CH2) on its successful merger with Paragon Care Limited (Paragon Care), which completed on 3 June 2024.  

CH2 is a leading Australian integrated distributor and wholesaler of pharmaceuticals, medical consumables, nutritional products, over-the-counter (OTC) items, medical equipment and medical supplies.

Paragon Care is an Australia-based supplier of durable medical equipment, medical devices and consumable medical products and maintenance of technical medical equipment to the health, aged care and veterinary markets.

The merger is expected to create a leading healthcare wholesaler, distributor and manufacturer operating across growing healthcare markets in Australia, New Zealand and Asia, with a post-completion indicative market capitalisation of over $600 million.

Baker McKenzie co-lead lawyers, Steven Glanz and Lizzie Lu, stated: "We are delighted to assist CH2 on this transformational transaction. This strategic merger is expected to capitalise on and strengthen the combined operational capabilities of the two businesses in these rapidly growing markets."

The Baker McKenzie team comprised: Steven Glanz, Lizzie Lu and Louise Hang.
Explore Our Newsroom